European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

A decisive step has been taken in the Vyndaqel market access procedure for wild type and hereditary transthyretin amyloidosis cardiomyopathy

Good news for Brazil

Alnylam received market authorization for Patisiran in Brazil

Last week, Brazil obtained marketing authorization for Tafamidis for ATTR cardiomyopathy (ATTR-CM)

The refund approval process will begin now. It is important to note that in the past two months, Brazil has experienced 2 other important events.

Good News

A decisive first step was taken this week in the Vyndaqel market access procedure for TTR amyloid cardiomyopathies.

Berlin meeting ATTR amyloidosis

The 2nd European meeting for ATTR amyloidosis for doctors and patients was held in Berlin the 2 and 3 of September. Read more about the conclusions and see the presentations.